Portable, Full-body CT Scanner Gets FDA Approval
NeuroLogica Corp. has received FDA approval for their portable, full-body, multi-slice CT scanner known as the BodyTom, the company announced this week.
NeuroLogica Corp. has received FDA approval for their portable, full-body, multi-slice CT scanner known as the BodyTom, the company announced this week.
The machine, which the company says is the first of its kind, received 501(k) clearance. The BodyTom is a battery-powered 32-slice CT with an 85 cm gantry and 60cm field of view, and it’s designed to be transported from room to room. It is DICOM 3.1 compliant and compatible with PACS, and other systems, the company said.
“Bringing high resolution imaging technology to the patient rather than moving patients to obtain this kind of vital information for a broad range of applications has to be the future," Dr. Howard Yonas, Chief of Neurosurgery at University of New Mexico Medical Center, said in the company press release. "The ability to bring such a powerful and high quality 32 slice CT scanner into the operating room for intra-operative scanning should have a significant impact on improving care and surgical outcomes.”
The Danvers, Mass.-based company also developed the portable head CT scanner, CereTom. The mobile unit was designed to scan patients suspected of traumatic brain injury and can fit through hospital doorways to perform scans from perfusion imaging to CT angiography.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
